Xinhua Pharmacy Chengtai Ruisha Jinliqu District Only Designated Pharmacy
Release time:
2020-08-14
Xinhua Pharmacy Chengtai Ruisha Jinliqu Area's Only Designated Pharmacy
News Recently, the third generation EGFR-TKI lung cancer targeted drug Tarisha (AZD9291 ) developed by AstraZeneca Company was approved by the China Food and Drug Administration for listing. Xinhua Pharmacy, the peak pharmacy, has become the only designated pharmacy in Tereza in Jinliqu area, and will also be the designated service point for Tereza's charity drug donation.
Tagrisso is the third generation oral, irreversible selective EGFR mutation inhibitor developed by AstraZeneca. It is the first tumor drug to be listed in the world and the first approved tumor drug for EGFR T790M mutation-positive locally advanced or metastatic non-small cell lung cancer in China. Tagrisso is a drug that treats a specific mutation in a gene that affects 40% of Asian lung cancer patients, higher than the proportion in Caucasians.
In order to reduce the financial burden of patients and their families, the China Charity Federation has launched the Terrisa Charity Assistance Project. The assistance mode is divided into two stages. Patients who meet the medical standards of the project will take the medicine continuously for 4 months at their own expense. After the project is approved, the first phase can receive up to 8 months of drug assistance, and the project will automatically withdraw when it expires; after the patient withdraws from the project in the first phase, if evaluated by the project doctor, he can still benefit from the drug treatment. The patient applies for re-admission after taking the medicine at his own expense for 3 months in a row. After approval, he can obtain drug assistance until the disease progresses. After investigation and evaluation in various aspects, Xinhua Pharmacy has become the designated service point for charity drug donation in Terisa in Jinliqu area.
Xinhua Pharmacy is adjacent to Jinhua People's Hospital and is a designated pharmacy for serious illness medical insurance in Jinhua City. The drugs are fully equipped. All hardware facilities are perfect. For drugs that need to be refrigerated, pharmacies have special refrigerators for storage. The refrigerators are equipped with monitoring probes, which are connected to the mobile phone system. If the temperature is abnormal, SMS alarm will be issued. Xinhua Pharmacy not only emphasizes improving the service awareness of the staff, but also focuses on improving the professional skills of the staff, satisfying customers through rich professional knowledge and high-quality service, retaining customers with sincerity, care, concentration and love, and enhancing the image of the store. All these provide a competitive advantage in hardware and software for Xinhua Pharmacy to become a designated service point for many varieties of charitable drug gifts. In addition to Tereza, Xinhua Pharmacy has previously been a designated service point for many varieties of charity drugs such as Iressa, Gnico, Herceptin and Libitai. (Tang Wenshu and Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page